Home > Back to Category > Report Information

The CNS Market 2010 Report

NeuroInsights, LLC
May 1, 2010
515 Pages - SKU: NEI2735440

Abstract Table of Contents Search inside this report Related Reports

Drugs, Biologics, Stem Cells, Devices and Diagnostics for the Brain and Nervous System: Market Analysis and Strategic Investment Guide of the Global Neurological Disease and Psychiatric Illness Markets

Now in its sixth year, The CNS Market 2010 Report is an expanded and updated 500 page report of brain and nervous system markets and treatments. It is the only publication to provide a comprehensive pipeline and market analysis to help investors, companies and entrepreneurs easily identify opportunities, understand the competitive landscape, determine risks and understand the dynamics of rapidly changing CNS markets.

The report includes detailed information on products in development globally for over 18 indications at 800 companies including Alzheimer's, addiction, ALS, anxiety, depressive disorders, epilepsy, migraine, mild cognitive impairment, Huntington's, multiple sclerosis, obesity, pain, Parkinson's, schizophrenia, age-related macular degeneration, sensory disorders, sleep disorders, and stroke.

The CNS Market 2010 Report provides a unified market-based framework to help executives, investors, and governments easily identify opportunities, understand the competitive landscape and visualize the dynamics of these rapidly growing markets.

More than 500 profiles of public and private neurotech companies including drugs, devices and diagnostics
12 most active neurotech venture capital firms profiled with investments by market segment and U.S. neurotech venture capital trends (1999-Q12010)
Neurotech IPOs (2004-Q12010), M&A (2004-Q12010), Partnering and Licensing deals (2005-Q12010) and public neurotech stock performance
Pipelines and market analysis for 18 brain and nervous system illnesses including: addiction, Alzheimer's disease, anxiety, attention disorders, depression, epilepsy, hearing loss, insomnia, mild cognitive impairment, migraine, multiple sclerosis, obesity, pain, Parkinson's disease, retinal disorders, schizophrenia and stroke
Analysis of biological basis, current treatment options, and emerging therapeutic strategies
Analysis of compounds, cell therapies and devices in clinical trials (and abandoned) by company, mechanism of action and stage of development for each indication
Global and US market size, worldwide revenues for each indication
Extensive discussion of specific technological, demographic, regulatory and intellectual property

1: Executive Summary: The Brain Industry Revealed; Investment Risks and Opportunities; Translating Neuroscience into Neurotech; The Neurotech Market Opportunity; NASDAQ NeuroInsights Neurotech Index; Neurotechnology and Society; Key Industry Facts and Findings; A Brief History of the Science Behind Neurotechnology
2: Trends and Drivers: Converging Technology Drivers; Demographic Drivers; Social Drivers; Economic Drivers; Research Funding; Regulatory Trends; Intellectual Property Trends
3: Neuropharmaceutical Sector: Neuropharmaceutical Sector Overview; Neurology Markets and Pipelines; Psychiatry Markets and Pipelines; Sensory Markets and Pipelines
4: Stem Cells and Neuroregeneration: Defining Stem Cell Markets and Players; Stem Cell Approaches; Markets and Treatments in Development
5: Neurodevice Sector: Neurodevice Sector Overview; Neuroprosthetic Devices; Neuromodulation Devices; Neuromodulation Device Clinial Trials and Recent Approvals; Deep Brain Stimulation; Transcranial Magnetic Stimulation (TMS); Spinal Cord Stimulation (SCS); Vagus Nerve Stimulation (VNS); Peripheral Stimulation; Neurosurgical devices; Neurovascular Intervention

Neurosoftware

Attention Deficit Disorder

Cognition and Aging

Emotional Wellbeing

Learning Disabilities and Autism

Pain

6: Neurodiagnostics Sector

Neurodiagnostic Sector Overview

FDA Approval and Insurance Reimbursement of Diagnostics

Neuroimaging Technologies

Computed Tomography (CT)

Magnetic Resonance Imaging (MRI)

Nuclear Medicine Imaging (PET, SPECT)

Electro-encephalography (EEG)

Magneto-encephalography (MEG)

In Vitro Diagnostics

In Vitro Diagnostics Regulatory Landscape

Emerging Diagnostics for Alzheimer’s Disease

Genetic Testing and Pharmacogenomics

Protein Biomarker Assays

Pattern Recognition in Diagnostics

Emerging Diagnostics for Psychiatry

Neuroinformatics

Diagnostic Software

7: Private Neurotechnology Investment

Private Investment in Neurotechnology

Venture Capital Investment Trends

Neurotech Venture Capital Investment

Investing in Neuropharmaceuticals

Investing in Stem Cells and Neuroregeneration

Investing in Neurodevices

Investing in Neurodiagnostics

Private Company Financings, 2010

Top financings 2004-2009

Leading Neurotech Venture Capital Firms

8: Public Neurotechnology Investment

Investing in Public Neurotech Companies

Neurotech Stock Universe

Neurotech Initial Public Offerings

Neurotech M&A Activity

NASDAQ NeuroInsights Neurotech Index

9: Neurotechnology Research Centers

Leading Neurotechnology Research Centers

University of California, San Francisco (UCSF)

University of California, Los Angeles (UCLA)

University of California, San Diego (UCSD)

Harvard

Stanford University

Massachusetts Institute of Technology (MIT)

Columbia University

Washington University, St. Louis

University College London (UCL)

Karolinska Institutet, Stockholm

RIKEN Brain Science Institute, Japan

Places to Watch

National Brain Research Centre (NBRC), India

Neurosciences Victoria, Australia (NSV)

Shanghai Institute of Brain Functional Genomics (SBG), China

10: Leading Neurotechnology Regions

The Global Neurotech Economy

Nexus Ranking and Methodology

Established Neurotech Nexus’

Emerging Neurotech Nexus’

Nascent Neurotech Nexus’

Conclusions and Policy Recommendations

11: Company Profiles

Neuropharmaceutical Companies: Private

Neuropharmaceutical Companies: Public

Neurodevice Companies: Private

Neurodevice Companies: Public

Neurodiagnostic Companies: Private

Neurodiagnostic Companies: Public

12: Index

The CNS Market 2010 Report: Exhibits, Tables, and Charts

1-1: Number of Individuals Afflicted by Indication, US and Worldwide, Top 15 Indications

1-2: Global Pharmaceutical Sales by Indication, 2009

1-3: Neurotechnology Industry Taxonomy

1-4: Proportion of Patient Population Segmented by Neurotech Market Opportunity

1-5: NASDAQ NeuroInsights Neurotech Index Performance vs. S&P500, NASQAQ Composite, and NASDAQ Biotechnology Index

2-1: Projected Percentage Increase in Global Populations aged 65 and over, 1994-2020

2-2: Neuropharmaceutical Patent Expirations and Generic Competition, 2003-2012

2-3: Neurotechnology Patent Approvals, US, 1985-2007

2-4: Neuropharmaceutical Patent Approvals, US, 1985-2007

2-5: Neurodevice Patent Approvals, US, 1985-2007

2-6: Neurodiagnostic Patent Approvals, US, 1985-2007

2-7: Selected US Foundations with a Significant focus on Brain Research and Education

2-8: Most Generous Philanthropists for Medical and Brain Research

2-9: Global Stem Cell Policy Map

3-1: Neuropharmaceutical Revenues by Indication (2009)

3-2: FDA Pharmaceutical Approval Process

3-3: Big Pharma neuropharmaceutical revenues

3-4: Neuropharmaceutical Partnering and Licensing Deals 2004-Q1 2010

3-5: Clinical Trials for Alzheimer’s disease (company, compound, phase, mechanism)

3-6: Worldwide revenues of leading anti-epileptics (2004-2009)

3-7: Clinical Trials for Epilepsy (company, compound, phase, mechanism)

3-8: Clinical Trials for Migraine (company, compound, phase, mechanism)

3-9: Clinical Trials for Multiple sclerosis (company, compound, phase, mechanism)

3-10: Clinical Trials for Mild Cognitive impairment (company, compound, phase, mechanism)

3-11: Clinical Trials for Parkinson’s disease (company, compound, phase, mechanism)

3-12: Clinical Trials for sleep disorders (company, compound, phase, mechanism)

3-13: Clinical Trials for stroke Treatment (company, compound, phase, mechanism)

3-14: Number of People with Addiction and Impulse Control Disorders (WW and US)

3-15: Clinical Trials for addition and substance abuse (company, compound, phase, mechanism)

3-16: Clinical Trials for anxiety disorders (company, compound, phase, mechanism)

3-17: Clinical Trials for ADHD (company, compound, phase, mechanism)

3-18: Clinical Trials for Depressive disorders (company, compound, phase, mechanism)

3-19: Clinical Trials for Obesity Treatment (company, compound, phase, mechanism)

3-20: Clinical Trials for Schizophrenia and psychosis (company, compound, phase, mechanism)

3-21: Clinical Trials for Retinal disorders (company, compound, phase, mechanism)

3-22: Clinical Trials for Pain (company, compound, phase, mechanism)

4-1: FDA Classification and Approval Process for Medical Devices

4-2: Neurodevice Acquisition and Investment Activity: Medtronic, Boston Scientific, J&J

4-3: Neurodevice Markets (Neuroprosthetic, Neuromodulation, Neurosurgical, Neurofeedback)

4-4: Neuromodulation Device Clinical Trials

5-1: Neurodiagnostics Markets and Annual Growth (Neuroimaging, In Vitro Diagnostics, Neuroinformatics)

5-2: FDA Approval and Insurance Reimbursement of Diagnostics

5-3: Neuroimaging Technology (CT, MRI, fMRI, PET, SPECT, EEG, MEG)

5-6: Alzheimer’s Disease Neuroimaging Initiative

5-7: Neuroinformatics Data Storage

5-8: Paul Allen Brain Atlas Project and IBM Blue Brain Project

6-1: Total US Venture Capital Investment, 1999-2009

6-2: US Life Science Venture Capital Investment, 1999-2009

6-3: US Neurotechnology Venture Capital Investment, 1999-2009

6-4: Neurotech as Percent of Life Science Venture Investment, 1999-2009

6-5: Top Five Neurotechnology Venture Capital Financings, 2001-2009

6-6: Top 12 Neurotech Venture Capital Firms with Investments

7-1: Neurotechnology Initial Public Offerings US, 2004-Q1 2010

7-2: Selected Neurotech M&A Activity, 2004-Q1 2010

7-3: Neurotech Index Companies 2010

7-4: Neurotech Index Company Fundamentals

7-5: Index Company Performance

8-1 Leading Neurotechnology Research Centers

8-2 Neurotech Research Centers and Affiliated Institutes, Funding, Recent Significant Investments, Reputation, Translation of Discoveries to Industry

8-3: UCSF

8-4: UCLA

8-5: Harvard University

8-6: Stanford University

8-7: MIT

8-8: Columbia University

8-9: Washington University

8-10: University College London

8-11: Karolinska Institute

8-12: RIKEN Brain Science Institute

9-1 NeuroInsights’ Leading Neurotech Nexus Ratings

9-2 Conclusions and Policy Recommendations

10-1 Neuropharmaceutical Companies Private Profiles (status, funding, location, investment, descriptions, investors)

10-2 Neuropharmaceutical Companies Public Profiles (status, symbol, HQ, market cap revenues, description)

10-3 Neurodevice Companies Private Profiles (status, funding, location, investment, descriptions, investors)

10-4 Neurodevice Companies Public Profiles (status, symbol, HQ, market cap revenues, description)

10-5 Neurodiagnostic Companies Private Profiles (status, funding, location, investment, descriptions, investors)

10-6 Neurodiagnostic Companies Public Profiles (status, symbol, HQ, market cap revenues, description)

The CNS Market 2010 Report

Share this report

Other tasks

Research Assistance

Related Markets

CNS/Neurology Reports

Free Alert Me service